Characteristics of donors in the development and internal validation cohort (TransplantLines) and external validation cohort (Mayo) before and after donation
| . | Development cohort . | Internal validation cohort . | External validation cohort (Mayo) . | |||
|---|---|---|---|---|---|---|
| Variable . | Pre-donation . | Post-donation . | Pre-donation . | Post-donation . | Pre-donation . | Post-donation . |
| Number | 511 | 511 | 509 | 509 | 1094 | 1094 |
| Age (years) | 53 (11) | 53 (11) | 53 (11) | 53 (11) | 45 (12) | 46 (12) |
| Sex (male), n (%) | 250 (49) | 246 (48) | 438 (40) | 438 (40) | ||
| Weight (kg) | 80 (13) | 79 (13) | 80 (14) | 80 (14) | 81 (16) | 81 (17) |
| Length (cm) | 175 (9) | 174 (9) | 175 (10) | 175 (10) | 171 (9) | 171 (9) |
| Body mass index (kg/m2) | 26 (3) | 26 (3) | 26 (4) | 26 (4) | 28 (5) | 28 (5) |
| Body surface area (m2) | 1.95 (0.19) | 1.94 (0.19) | 1.96 (0.20) | 1.95 (0.20) | 1.93 (0.22) | 1.93 (0.22) |
| mGFR (mL/min/1.73 m2) | 101 (15) | 64 (11) | 101 (17) | 64 (11) | 102 (18) | 66 (13) |
| eGFRCKD-EPI (mL/min/1.73 m2) | 86 (14) | 57 (12) | 88 (14) | 57 (12) | 89 (15) | 58 (12) |
| Systolic blood pressure (mmHg) | 126 (13) | 124 (12) | 127 (13) | 124 (12) | 120 (15) | 119 (14) |
| Diastolic blood pressure (mmHg) | 75 (9) | 76 (8) | 76 (8) | 76 (9) | 73 (9) | 72 (9) |
| Proteinuria (g/24 h), median (IQR) | 0.00 (0.00–0.00) | 0.00 (0.00–0.00) | 0.00 (0.00–0.00) | 0.00 (0.00–0.00) | 0.04 (0.03–0.06) | 0.06 (0.04–0.09) |
| Serum creatinine (µmol/L) | 79 (14) | 114 (21) | 77 (14) | 114 (22) | 79 (14) | 112 (34) |
| . | Development cohort . | Internal validation cohort . | External validation cohort (Mayo) . | |||
|---|---|---|---|---|---|---|
| Variable . | Pre-donation . | Post-donation . | Pre-donation . | Post-donation . | Pre-donation . | Post-donation . |
| Number | 511 | 511 | 509 | 509 | 1094 | 1094 |
| Age (years) | 53 (11) | 53 (11) | 53 (11) | 53 (11) | 45 (12) | 46 (12) |
| Sex (male), n (%) | 250 (49) | 246 (48) | 438 (40) | 438 (40) | ||
| Weight (kg) | 80 (13) | 79 (13) | 80 (14) | 80 (14) | 81 (16) | 81 (17) |
| Length (cm) | 175 (9) | 174 (9) | 175 (10) | 175 (10) | 171 (9) | 171 (9) |
| Body mass index (kg/m2) | 26 (3) | 26 (3) | 26 (4) | 26 (4) | 28 (5) | 28 (5) |
| Body surface area (m2) | 1.95 (0.19) | 1.94 (0.19) | 1.96 (0.20) | 1.95 (0.20) | 1.93 (0.22) | 1.93 (0.22) |
| mGFR (mL/min/1.73 m2) | 101 (15) | 64 (11) | 101 (17) | 64 (11) | 102 (18) | 66 (13) |
| eGFRCKD-EPI (mL/min/1.73 m2) | 86 (14) | 57 (12) | 88 (14) | 57 (12) | 89 (15) | 58 (12) |
| Systolic blood pressure (mmHg) | 126 (13) | 124 (12) | 127 (13) | 124 (12) | 120 (15) | 119 (14) |
| Diastolic blood pressure (mmHg) | 75 (9) | 76 (8) | 76 (8) | 76 (9) | 73 (9) | 72 (9) |
| Proteinuria (g/24 h), median (IQR) | 0.00 (0.00–0.00) | 0.00 (0.00–0.00) | 0.00 (0.00–0.00) | 0.00 (0.00–0.00) | 0.04 (0.03–0.06) | 0.06 (0.04–0.09) |
| Serum creatinine (µmol/L) | 79 (14) | 114 (21) | 77 (14) | 114 (22) | 79 (14) | 112 (34) |
Values presented a mean (SD) unless stated otherwise. mGFR by iothalamate clearance; eGFR using the Chronic Kidney Disease Epidemiology Collaboration equation.
Characteristics of donors in the development and internal validation cohort (TransplantLines) and external validation cohort (Mayo) before and after donation
| . | Development cohort . | Internal validation cohort . | External validation cohort (Mayo) . | |||
|---|---|---|---|---|---|---|
| Variable . | Pre-donation . | Post-donation . | Pre-donation . | Post-donation . | Pre-donation . | Post-donation . |
| Number | 511 | 511 | 509 | 509 | 1094 | 1094 |
| Age (years) | 53 (11) | 53 (11) | 53 (11) | 53 (11) | 45 (12) | 46 (12) |
| Sex (male), n (%) | 250 (49) | 246 (48) | 438 (40) | 438 (40) | ||
| Weight (kg) | 80 (13) | 79 (13) | 80 (14) | 80 (14) | 81 (16) | 81 (17) |
| Length (cm) | 175 (9) | 174 (9) | 175 (10) | 175 (10) | 171 (9) | 171 (9) |
| Body mass index (kg/m2) | 26 (3) | 26 (3) | 26 (4) | 26 (4) | 28 (5) | 28 (5) |
| Body surface area (m2) | 1.95 (0.19) | 1.94 (0.19) | 1.96 (0.20) | 1.95 (0.20) | 1.93 (0.22) | 1.93 (0.22) |
| mGFR (mL/min/1.73 m2) | 101 (15) | 64 (11) | 101 (17) | 64 (11) | 102 (18) | 66 (13) |
| eGFRCKD-EPI (mL/min/1.73 m2) | 86 (14) | 57 (12) | 88 (14) | 57 (12) | 89 (15) | 58 (12) |
| Systolic blood pressure (mmHg) | 126 (13) | 124 (12) | 127 (13) | 124 (12) | 120 (15) | 119 (14) |
| Diastolic blood pressure (mmHg) | 75 (9) | 76 (8) | 76 (8) | 76 (9) | 73 (9) | 72 (9) |
| Proteinuria (g/24 h), median (IQR) | 0.00 (0.00–0.00) | 0.00 (0.00–0.00) | 0.00 (0.00–0.00) | 0.00 (0.00–0.00) | 0.04 (0.03–0.06) | 0.06 (0.04–0.09) |
| Serum creatinine (µmol/L) | 79 (14) | 114 (21) | 77 (14) | 114 (22) | 79 (14) | 112 (34) |
| . | Development cohort . | Internal validation cohort . | External validation cohort (Mayo) . | |||
|---|---|---|---|---|---|---|
| Variable . | Pre-donation . | Post-donation . | Pre-donation . | Post-donation . | Pre-donation . | Post-donation . |
| Number | 511 | 511 | 509 | 509 | 1094 | 1094 |
| Age (years) | 53 (11) | 53 (11) | 53 (11) | 53 (11) | 45 (12) | 46 (12) |
| Sex (male), n (%) | 250 (49) | 246 (48) | 438 (40) | 438 (40) | ||
| Weight (kg) | 80 (13) | 79 (13) | 80 (14) | 80 (14) | 81 (16) | 81 (17) |
| Length (cm) | 175 (9) | 174 (9) | 175 (10) | 175 (10) | 171 (9) | 171 (9) |
| Body mass index (kg/m2) | 26 (3) | 26 (3) | 26 (4) | 26 (4) | 28 (5) | 28 (5) |
| Body surface area (m2) | 1.95 (0.19) | 1.94 (0.19) | 1.96 (0.20) | 1.95 (0.20) | 1.93 (0.22) | 1.93 (0.22) |
| mGFR (mL/min/1.73 m2) | 101 (15) | 64 (11) | 101 (17) | 64 (11) | 102 (18) | 66 (13) |
| eGFRCKD-EPI (mL/min/1.73 m2) | 86 (14) | 57 (12) | 88 (14) | 57 (12) | 89 (15) | 58 (12) |
| Systolic blood pressure (mmHg) | 126 (13) | 124 (12) | 127 (13) | 124 (12) | 120 (15) | 119 (14) |
| Diastolic blood pressure (mmHg) | 75 (9) | 76 (8) | 76 (8) | 76 (9) | 73 (9) | 72 (9) |
| Proteinuria (g/24 h), median (IQR) | 0.00 (0.00–0.00) | 0.00 (0.00–0.00) | 0.00 (0.00–0.00) | 0.00 (0.00–0.00) | 0.04 (0.03–0.06) | 0.06 (0.04–0.09) |
| Serum creatinine (µmol/L) | 79 (14) | 114 (21) | 77 (14) | 114 (22) | 79 (14) | 112 (34) |
Values presented a mean (SD) unless stated otherwise. mGFR by iothalamate clearance; eGFR using the Chronic Kidney Disease Epidemiology Collaboration equation.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
